The effect of rare human sequence variants on the function of vesicular monoamine transporter 2

被引:13
作者
Burman, J
Tran, CH
Glatt, C
Freimer, NB
Edwards, RH
机构
[1] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Psychiat, San Francisco, CA USA
来源
PHARMACOGENETICS | 2004年 / 14卷 / 09期
关键词
monoamine transport; neurotransmitter transport; reserpine; serotonin; single nucleotide polymorphisms; tetrabenazine; VMAT2;
D O I
10.1097/00008571-200409000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The extent to which genetic variation in a population contributes to phenotypic variation depends on the frequency of sequence polymorphisms and the effect of these polymorphisms on function. The frequency of polymorphisms might also reflect the severity of their effects on function. We therefore examined the effect of very rare single nucleotide polymorphisms (SNPs) on the activity of the vesicular monoamine transporter 2 (VMAT2, SLC18A2), a gene implicated in neuropsychiatric disease. Of the two rare SNPs identified in an ethnically diverse population, neither eliminates transport, but one that involves replacement of a highly conserved residue with a very similar amino acid impairs substrate recognition. This variant, and another affecting an unconserved residue, also affect inhibition by the clinically used drug reserpine. Because VMAT2 influences a form of toxicity similar to Parkinson's disease, we extended the analysis to two SNPs identified in a population with Parkinson's disease. These two SNPs have no detectable effect on most aspects of VMAT2 function, but one that affects a highly conserved residue may increase sensitivity to the inhibitor tetrabenazine. The results illustrate the relationship between conservation of the affected residue, the nature of the substitution and effects on substrate versus inhibitor interaction. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:587 / 594
页数:8
相关论文
共 33 条
[11]   Heterozygous VMAT2 knockout mice display prolonged QT intervals: possible contributions to sudden death [J].
Itokawa, K ;
Sora, I ;
Schindler, CW ;
Itokawa, M ;
Takahashi, N ;
Uhl, GR .
MOLECULAR BRAIN RESEARCH, 1999, 71 (02) :354-357
[12]   Variability of neurotransmitter concentration and nonsaturation of postsynaptic AMPA receptors at synapses in hippocampal cultures and slices [J].
Liu, GS ;
Choi, SW ;
Tsien, RW .
NEURON, 1999, 22 (02) :395-409
[13]  
Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125
[14]   A CDNA THAT SUPPRESSES MPP+ TOXICITY ENCODES A VESICULAR AMINE TRANSPORTER [J].
LIU, YJ ;
PETER, D ;
ROGHANI, A ;
SCHULDINER, S ;
PRIVE, GG ;
EISENBERG, D ;
BRECHA, N ;
EDWARDS, RH .
CELL, 1992, 70 (04) :539-551
[15]   IDENTIFICATION OF RESIDUES INVOLVED IN SUBSTRATE RECOGNITION BY A VESICULAR MONOAMINE TRANSPORTER [J].
MERICKEL, A ;
ROSANDICH, P ;
PETER, D ;
EDWARDS, RH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25798-25804
[16]   Genetic perspectives on the serotonin transporter [J].
Murphy, DL ;
Li, Q ;
Engel, S ;
Wichems, C ;
Andrews, A ;
Lesch, KP ;
Uhl, G .
BRAIN RESEARCH BULLETIN, 2001, 56 (05) :487-494
[17]   Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine [J].
Peter, D ;
Vu, T ;
Edwards, RH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :2979-2986
[18]  
PETER D, 1994, J BIOL CHEM, V269, P7231
[19]  
PETER D, 1995, J NEUROSCI, V15, P6179
[20]   MOLECULAR-CLONING OF A PUTATIVE VESICULAR TRANSPORTER FOR ACETYLCHOLINE [J].
ROGHANI, A ;
FELDMAN, J ;
KOHAN, SA ;
SHIRZADI, A ;
GUNDERSEN, CB ;
BRECHA, N ;
EDWARDS, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (22) :10620-10624